Upon completion of this activity, participants should be able to:
Describe CLD management recommendations/guidelines for new treatments and describe current guidelines for the diagnosis and management of gastrointestinal disorders.
Utilize new therapies and employ an evidence-based approach to the management of gastrointestinal disorders to optimize treatment results for patients with CLD.
Identify new advances and assess their potential impact on clinical practice.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Chronic Liver Disease Foundation (CLDF). Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this Live Activity for a maximum of 4.0 AMA PRA Category 1 Credits™ on Friday, March 11th and 4.0 AMA PRA Category 1 Credits™ on Saturday, March 12th. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, staff, and reviewers of Chronic Liver Disease Foundation (CLDF) and Purdue University College of Pharmacy have no relationships to disclose.
This activity is supported by an educational grant from AbbVie, Gilead Sciences, Intercept Pharmaceuticals, Inc., Ipsen Innovation S.A.S.,
Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals and Salix Pharmaceuticals.